Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The clinical evidence from the QuANTUM-First trial indicates that quizartinib improves overall survival compared to placebo, with a hazard ratio of 0.78 (95% CI 0.62 to 0.98). However, the lack of direct comparison with midostaurin and the uncertainties surrounding indirect comparisons limit the strength of the evidence. Thus, while there is moderate benefit, it is not compelling enough to warrant a higher rating.
Cost effectiveness
The cost-effectiveness estimates for quizartinib are within the acceptable range of £20,000 per QALY gained, as noted by the committee. The economic model, despite some uncertainties, suggests that quizartinib is a defensible option in terms of cost-effectiveness.
Quality of life
The document does not provide specific data on HRQoL improvements associated with quizartinib. While there are indications that patients would welcome a new treatment option, the absence of validated tools showing significant improvements in quality of life leads to a rating of minimal impact.
Supporting Domains
Safety and Adverse Effects
Quizartinib has a very good safety profile, with mostly mild or moderate adverse events reported. The document indicates that the adverse effects are manageable, which supports a strong rating for safety.
Comparator Selection
The primary comparator, midostaurin, was not directly tested against quizartinib, leading to reliance on indirect comparisons. While midostaurin is the most relevant comparator, the lack of direct evidence introduces uncertainty.
Patient Population and Subgroups
The trial population for quizartinib is broadly representative of the intended patient population with FLT3-ITD-positive AML. However, there are some limitations regarding age and other demographic factors that could affect generalizability.
Care Pathway Integration
Quizartinib can be integrated into existing treatment pathways with minor adjustments, as it is used in combination with standard chemotherapy. This indicates a manageable integration process.
Resource Use and Cost Implications
The budget impact of quizartinib is considered manageable, especially with the commercial arrangement providing a discount. This suggests that the resource implications are justifiable.
Evidence Quality and Robustness
While the evidence from the QuANTUM-First trial is robust, the reliance on indirect comparisons and the uncertainties surrounding them introduce some concerns about the overall robustness of the evidence.
Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty regarding the indirect treatment comparisons and the overall survival benefits of quizartinib. The committee noted that many results were not statistically significant, which raises concerns about broader impacts.
